What are other Names for this Test? (Equivalent Terms)
- Gene Mutation Analysis for Large Cell Neuroendocrine Carcinoma of Kidney
- Molecular Testing for LCNEC of Kidney
- Test for Molecular Diagnosis of Large Cell Neuroendocrine Carcinoma of Kidney
What is Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney? (Background Information)
- Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney is a genetic test that is helpful in aiding a diagnosis of large cell neuroendocrine carcinoma of kidney. The lab test results may also be subsequently useful in taking appropriate treatment decisions
- Large cell neuroendocrine carcinoma (LCNEC) of kidney is a type of renal cell carcinoma or kidney cancer. The malignant tumor generally affects adult males and females; though, it is more common in older individuals
- The exact cause for the development of LCNEC of kidney is presently unknown, but it may be due to genetic factors. The risk factors for developing the tumors are not well established
- However, the factors that may contribute to the development of kidney cancers include a positive family history of kidney cancer, smoking, exposure to toxins, high blood pressure, and obesity
- The typical symptoms of large cell neuroendocrine carcinoma of kidney are blood in urine, a lump on the side, flank pain, unexplained fever and unexplained weight loss. LCNEC of kidney may give rise to complication such as spread of cancer to other parts of the body
The cause of large cell neuroendocrine carcinoma of kidney may be due to genetic mutations. Currently, studies indicate the following defects:
- Loss of heterozygosity and X-inactivation patterns
The above genetic abnormalities can be detected using molecular studies, which may play a significant role in identifying the tumor type, and in some cases, helping the healthcare provider take appropriate treatment decisions.
The molecular testing, in general, can be performed using a variety of methods. Some of these methods include:
- In situ hybridization technique, such as fluorescence in situ hybridization (FISH)
- Immunohistochemistry (IHC)
- Next-generation sequencing (NGS)
- Polymerase chain reaction (PCR)
- Comparative genomic hybridization (CGH)
- Karyotyping including spectral karyotyping
- mRNA analysis
- Tissue microarrays (TMAs)
- Southern blot test
- Northern blot test
- Western blot test
- Eastern blot test
The methodology used for LCNEC of kidney may vary from one laboratory to another.
Note: Molecular testing has limitations due to the molecular method and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.
What are the Clinical Indications for performing the Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney Test?
Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney is undertaken in the following situations:
- To assist (and in some cases, confirm) the initial diagnosis of LCNEC of kidney
- To distinguish other tumors/conditions that have similar histological features, when examined by a pathologist under the microscope
- To help in determining treatment options
- To confirm recurrence of the tumor: Tumor recurrence can either be at the original tumor site, or at a distant location (away from the initial site)
How is the Specimen Collected for Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney?
Following is the specimen collection process for Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney:
The specimen sample requirements may vary from lab to lab. Hence, it is important to contact the testing lab for exact specimen requirements, before initiating the testing process.
- Sample on which the test is performed may include:
- Fresh tumor tissue during biopsy
- Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
- Unstained tissue slides
- Process of obtaining the sample: As outlined by the laboratory testing facility
- Preparation required: As outlined by the laboratory testing facility
- In some cases, a different source of specimen (such as peripheral blood, bone marrow biopsy specimen, or other body fluids) may be acceptable to the laboratory performing the test
- Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing
- Depending on the location of testing, it may take up to 2 weeks’ turnaround time, to obtain the test results
- Many hospitals preserve the paraffin blocks for at least 7 years. In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tumor specimen over time
Cost of Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney:
- The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, out-of-network and in-network of your healthcare providers and healthcare facilities
- In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care that is necessary (if any)
What is the Significance of the Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney Result?
The significance of Molecular Testing for Large Cell Neuroendocrine Carcinoma of Kidney is explained:
- Presence of a positive test result helps aid, and in some cases, confirm the diagnosis of LCNEC of kidney
- The result can help exclude other tumors with similar histological features
- It can help determine the prognosis of the patient
- In some cases, the test results may help in taking treatment decisions
The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.
Additional and Relevant Useful Information:
- Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures may perform this test
- Additional mutations are still being discovered in many of these tumors. This may further contribute towards tumor diagnosis and treatment. Please consult with your healthcare provider for any information updates
Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.
What are some Useful Resources for Additional Information?
Please visit our Laboratory Procedures Center for more physician-approved health information:
References and Information Sources used for the Article:
https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 03/05/2017)
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 03/05/2017)
http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 03/05/2017)
http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 03/05/2017)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710086/ (accessed on 04/14/17)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290282/ (accessed on 04/14/17)
http://www.pagepress.org/journals/index.php/rt/article/view/rt.2009.e37/1625 (accessed on 04/14/17)
http://path.upmc.edu/cases/case692/dx.html (accessed on 04/14/17)
Helpful Peer-Reviewed Medical Articles:
Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)
Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)
Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)
Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17
Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524
Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368
Travis, W. D., Linnoila, R. I., Tsokos, M. G., Hitchcock, C. L., Cutler Jr, G. B., Nieman, L., ... & Doppman, J. (1991). Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. The American journal of surgical pathology, 15(6), 529-553.
Evans, A. J., Humphrey, P. A., Belani, J., van der Kwast, T. H., & Srigley, J. R. (2006). Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. The American journal of surgical pathology, 30(6), 684-693.
Kaufmann, O., & Dietel, M. (2000). Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. HISTOPATHOLOGY-OXFORD-, 36(1), 8-16.
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., ... & Rolland, F. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125-134.
Agoff, S. N., Lamps, L. W., Philip, A. T., Amin, M. B., Schmidt, R. A., True, L. D., & Folpe, A. L. (2000). Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Modern Pathology, 13(3), 238-242.
Gnepp, D. R. (1991). Small cell neuroendocrine carcinoma of the larynx. ORL, 53(4), 210-219.
Masumori, N., Thomas, T. Z., Chaurand, P., Case, T., Paul, M., Kasper, S., ... & Matusik, R. J. (2001). A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research, 61(5), 2239-2249.